Literature DB >> 12911509

Soluble E-selectin and soluble ICAM-1 levels as markers of the activity of atopic dermatitis in children.

Albert Wolkerstorfer1, Huub F J Savelkoul, Flora B de Waard van der Spek, Herman J Neijens, Tim van Meurs, Arnold P Oranje.   

Abstract

The expression of adhesion molecules is up-regulated in the skin of atopic dermatitis (AD) patients, and the levels of the soluble adhesion molecules sE-selectin and sICAM-1 have been reported to reflect the endothelial activation in the skin of AD patients. The objective of the study was to investigate the relationship between symptom score and levels of sE-selectin, sICAM-1 and sVCAM-1 before and after 2 weeks of treatment. Eighteen children with an exacerbation of AD were admitted and treated with corticosteroid dilutions under occlusive wet dressings (wet-wrap treatment). Symptom score (objective SCORAD) and levels of sE-selectin, sICAM-1, and sVCAM-1 were assessed before and after 2 weeks of treatment. A significant correlation between the objective SCORAD before treatment and the level of sE-selectin (p < 0.05), but not the level of sICAM-1 (p = 0.7) or sVCAM-1 (p = 0.5) was observed. The treatment resulted in a high degree of remission, which was reflected by a significant decrease in the level of sICAM-1 (p < 0.01), whereas there was only a trend in the level of sE-selectin to decrease (p = 0.08). The level of sE-selectin after 2 weeks of treatment still correlated significantly with the objective SCORAD before treatment (p < 0.005). Soluble E-selectin is a relative objective marker for the severity of AD. SCORAD is a treatment-sensitive symptom of AD, whereas E-selectin may be a more stable underlying systemic representation of AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12911509     DOI: 10.1034/j.1399-3038.2003.00057.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  4 in total

1.  Autoantibodies against CD28 are associated with atopic diseases.

Authors:  K Neuber; B Mähnss; C Hübner; H Gergely; M Weichenthal
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

Review 2.  Targeting selectins and selectin ligands in inflammation and cancer.

Authors:  Steven R Barthel; Jacyln D Gavino; Leyla Descheny; Charles J Dimitroff
Journal:  Expert Opin Ther Targets       Date:  2007-11       Impact factor: 6.902

Review 3.  Specific immunotherapy in atopic dermatitis.

Authors:  Jungsoo Lee; Chang Ook Park; Kwang Hoon Lee
Journal:  Allergy Asthma Immunol Res       Date:  2014-11-25       Impact factor: 5.764

4.  Pilot study of a customized nanotextile wet garment treatment on moderate and severe atopic dermatitis: A randomized clinical trial.

Authors:  Huiling He; Mark Jean-Aan Koh; Haur Yueh Lee; Seng Bin Ang
Journal:  Pediatr Dermatol       Date:  2019-10-30       Impact factor: 1.588

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.